Publications

Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study  (2020)

Authors:
Maines, Evelina; Tadiotto, Elisa; Morandi, Grazia; Fedrizzi, Michela; Gaudino, Rossella; Cavarzere, Paolo; Guzzo, Alessandra; Antoniazzi, Franco
Title:
Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study
Year:
2020
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Format:
A Stampa
Referee:
Name of journal:
JOURNAL OF PEDIATRIC GENETICS
ISSN of journal:
2146-4596
N° Volume:
9
Number or Folder:
2
Page numbers:
93-100
Keyword:
children; hypocalcemia; neridronate; osteogenesis imperfecta; vitamin D deficiency
Short description of contents:
The use of intravenous bisphosphonates has been linked to hypocalcemia both in children and adults with osteogenesis imperfecta (OI). The aims of this study were: (1) to investigate the incidence of hypocalcemia in the first 48 hours (T48) after neridronate infusion in a pediatric population with OI and (2) to assess any correlation between the baseline values of calcium, vitamin D (25-hydroxyvitamin D) and bone turnover markers, and the postinfusion calcium values. We conducted a prospective observational study on 37 pediatric patients. All patients were treated with a single infusion of neridronate at a dose of 1 to 2 mg/kg. The study provided two postinfusion reassessments: 24 hours (T24) and T48 after neridronate administration. Hypocalcemia was observed in 11% of patients at T24 and in 50% of patients at T48 from neridronate infusion. We observed a positive linear correlation between the baseline vitamin D values and postinfusion calcium values, both at baseline and at T24 and T48. Hypocalcemia was mild and asymptomatic in all cases. Postinfusion calcium levels were related to baseline vitamin D levels. Consequently, low vitamin D levels should be considered a significant risk factor for hypocalcemia and should be carefully investigated and treated before neridronate infusion.
Product ID:
117931
Handle IRIS:
11562/1030771
Last Modified:
November 15, 2022
Bibliographic citation:
Maines, Evelina; Tadiotto, Elisa; Morandi, Grazia; Fedrizzi, Michela; Gaudino, Rossella; Cavarzere, Paolo; Guzzo, Alessandra; Antoniazzi, Franco, Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study «JOURNAL OF PEDIATRIC GENETICS» , vol. 9 , n. 22020pp. 93-100

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<back

Activities

Research facilities

Share